BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company. The Company is engaged in the research and development of cancer immunotherapy technology. The Company offers BriaVax, an immunotherapy vaccine. The Company is engaged in developing and advancing its BriaVax immunotherapy vaccine for patients with advanced breast cancer. The Company is also engaged in the research and development of its companion diagnostic product, BriaDx. The Company's BriaDx program is focused on analyzing samples obtained from patients previously treated with BriaVax along with co-analysis of previously manufactured vaccine lots. The Company's analysis methods include various technologies, including gene expression profiling by Illumina microarrays and human leukocyte antigen (HLA) typing by a high-resolution method. The Company is focused on understanding the mechanism of action (MoA) of BriaVax.